Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.74), $0.01 worse than the analyst estimate of ($0.73).
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia’s AI dominance funds historic $150 billion buyback
- Tigress Financial Partners Reiterates Buy Rating on Royal Caribbean Cruises (RCL)
- What will it take to fix the market’s weak breadth? Morgan Stanley weighs in
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
